Foghorn Therapeutics (FHTX) Competitors $4.58 -0.05 (-1.08%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$4.60 +0.01 (+0.33%) As of 06/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. AKBA, CVAC, ELVN, PAHC, COLL, AVDL, CRMD, NRIX, SNDX, and PHVSShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Akebia Therapeutics (AKBA), CureVac (CVAC), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Collegium Pharmaceutical (COLL), Avadel Pharmaceuticals (AVDL), CorMedix (CRMD), Nurix Therapeutics (NRIX), Syndax Pharmaceuticals (SNDX), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Akebia Therapeutics CureVac Enliven Therapeutics Phibro Animal Health Collegium Pharmaceutical Avadel Pharmaceuticals CorMedix Nurix Therapeutics Syndax Pharmaceuticals Pharvaris Akebia Therapeutics (NASDAQ:AKBA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Do analysts recommend AKBA or FHTX? Akebia Therapeutics currently has a consensus price target of $6.75, suggesting a potential upside of 89.08%. Foghorn Therapeutics has a consensus price target of $12.13, suggesting a potential upside of 164.74%. Given Foghorn Therapeutics' higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Does the media favor AKBA or FHTX? In the previous week, Akebia Therapeutics had 19 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 21 mentions for Akebia Therapeutics and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.93 beat Akebia Therapeutics' score of 0.87 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in AKBA or FHTX? Akebia Therapeutics received 376 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. However, 66.20% of users gave Foghorn Therapeutics an outperform vote while only 63.13% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformAkebia TherapeuticsOutperform Votes42363.13% Underperform Votes24736.87% Foghorn TherapeuticsOutperform Votes4766.20% Underperform Votes2433.80% Is AKBA or FHTX more profitable? Akebia Therapeutics has a net margin of -27.07% compared to Foghorn Therapeutics' net margin of -357.53%. Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-27.07% N/A -20.57% Foghorn Therapeutics -357.53%N/A -30.98% Do institutionals and insiders believe in AKBA or FHTX? 33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, AKBA or FHTX? Akebia Therapeutics has higher revenue and earnings than Foghorn Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$184.91M5.07-$51.92M-$0.21-17.00Foghorn Therapeutics$23.50M10.86-$98.43M-$1.36-3.37 Which has more volatility & risk, AKBA or FHTX? Akebia Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.04, indicating that its share price is 204% more volatile than the S&P 500. SummaryFoghorn Therapeutics beats Akebia Therapeutics on 10 of the 18 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.29M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-2.398.7827.1720.06Price / Sales10.86255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book-2.506.557.064.70Net Income-$98.43M$143.93M$3.23B$247.88M7 Day Performance11.17%3.97%2.89%2.66%1 Month Performance3.39%11.32%9.06%6.40%1 Year Performance-24.05%4.20%31.40%14.07% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.3627 of 5 stars$4.58-1.1%$12.13+164.7%-23.2%$255.29M$23.50M-2.39120AKBAAkebia Therapeutics4.4679 of 5 stars$3.83-3.5%$6.75+76.2%+221.6%$1.01B$184.91M-16.65430High Trading VolumeCVACCureVac4.3007 of 5 stars$4.48+1.6%$11.00+145.5%-4.2%$1.01B$523.70M8.15880Positive NewsELVNEnliven Therapeutics2.4734 of 5 stars$20.34-1.9%$37.25+83.1%-10.9%$998.06MN/A-10.7150Insider TradePAHCPhibro Animal Health3.8772 of 5 stars$24.23+0.6%$20.00-17.5%+45.6%$982.14M$1.19B50.481,860Positive NewsCOLLCollegium Pharmaceutical4.0547 of 5 stars$30.44+0.8%$43.75+43.7%-8.8%$978.10M$664.28M13.12210Positive NewsInsider TradeAVDLAvadel Pharmaceuticals2.171 of 5 stars$10.07+3.6%$19.43+92.9%-35.2%$974.16M$194.45M-12.7570Positive NewsAnalyst RevisionHigh Trading VolumeCRMDCorMedix0.478 of 5 stars$14.35+2.6%$15.00+4.5%+188.9%$973.29M$82.55M-17.7230Positive NewsNRIXNurix Therapeutics2.1359 of 5 stars$12.54-1.9%$30.18+140.6%-21.8%$956.00M$56.42M-4.34300SNDXSyndax Pharmaceuticals3.0091 of 5 stars$11.09-3.1%$35.91+223.8%-43.6%$954.26M$43.72M-3.06110Positive NewsPHVSPharvaris1.3895 of 5 stars$18.03+7.4%$37.25+106.6%+7.4%$942.79MN/A-6.4430Trending NewsAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies Akebia Therapeutics Competitors CureVac Competitors Enliven Therapeutics Competitors Phibro Animal Health Competitors Collegium Pharmaceutical Competitors Avadel Pharmaceuticals Competitors CorMedix Competitors Nurix Therapeutics Competitors Syndax Pharmaceuticals Competitors Pharvaris Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FHTX Stock Free FHTX Stock Alerts